2023 Bladder Cancer Canada-EMD Serono-Pfizer Quality Improvement Request for Proposals

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within unit

Memorial Deadline: Wednesday 12th, April 2023

External Deadline: Wednesday 19th, April 2023


Please note: UPDATED Application Due Date: April 19, 2023

Bladder Cancer Canada is the first and only patient advocacy organization dedicated solely to bladder cancer patients since it was created in 2009.

Bladder Cancer Canada’s vision is to support bladder cancer patients and their teams, increase awareness of bladder cancer among the general public and medical community as well as fund research which pursue the diagnosis, treatment and elimination of bladder cancer.

Pfizer and EMD Serono are very proud to partner with Bladder Cancer Canada to launch this Request for Proposals (RFP) program aimed at helping to improve the lives of people living with bladder cancer and help reduce the gap in funding of high-priority research topics that are relevant for patients, caregivers, healthcare professionals and systems, and scientists. Responses to this RFP will be reviewed by an Expert Review Panel led by Bladder Cancer Canada. The panel will be comprised of bladder cancer experts (patients and medical experts) and a Pfizer and EMD Serono Medical Affairs representative. The Expert Review Panel will make all final grant decisions.


Date RFP Issued: January 11, 2023

Geographic Scope: Canada

Clinical Area: Oncology – Genitourinary – Urothelial Carcinoma

Link to full RFP: 2023 Bladder Cancer Canada-EMD Serono-Pfizer Quality Improvement Request for Proposals

Application Due Date: March 30, 2023

Specific Area of Interest: The intent of this RFP is to encourage proposals for the implementation of strategies that will measurably improve the quality of care of patients with locally advanced/ metastatic bladder cancer. This type of Quality Improvement (QI) should consider aspects of quality such as clinical competence, outcomes and process assessment, program evaluation, quality indicators and quality assurance. For the purposes of this project, locally advanced or metastatic bladder cancer is defined as stage IV unresectable disease that has progressed beyond the bladder to the surrounding tissue or lymph nodes, or with overt metastases. Successful projects will incorporate quality improvement methods to overcome identified gaps or challenges, with the ultimate goal of optimizing the treatment and care of patients with metastatic bladder cancer, with a focus on strategies that will improve quality and length of life as there is, to date, no known cure. Potential concepts and ideas around areas for improvement may consider guideline-based care, overcoming identified barriers (e.g. clinical and treatment related factors, patient-related psychosocial factors and healthcare system or technological related barriers), etc.

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: March 13, 2023